Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Quest Diagnostics (DGX)

Quest Diagnostics presents long-term outlook at J.P. Morgan Healthcare Conference

Neutral Impact 2 of 5 other Written later

Quest Diagnostics filed a presentation from its January 12, 2026 appearance at the 44th Annual J.P. Morgan Healthcare Conference, where Chairman, CEO and President Jim Davis discussed strategy and market trends. The filing contains no new quarterly results, but it restates a long-term outlook for revenue, adjusted EPS and capital deployment through 2027.

Key points

  • Long-term outlook beyond 2025: 4% to 5% revenue CAGR and 7% to 9% adjusted EPS CAGR, with operating margins up 75 to 150 basis points by the end of 2027.
  • Targeted capital deployment for 2025 to 2027 includes $4.5 billion to $5.0 billion in operating cash flow and $3.0 billion to $3.3 billion in free cash flow.
  • Planned uses include about $1.5 billion for acquisitions, about $1.0 billion for dividends and about $0.7 billion for share repurchases.
  • The presentation says the capital deployment plan is consistent with what the company shared at its March 2025 Investor Day.

The filing

CompanyQuest Diagnostics (DGX)
Form8-K, current report
Filed with the SECJan 12, 2026, 4:37 PM ET
Accession number0000947871-26-000025

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.